Detecting Pathogens and Measuring the Immune Response to Disease

Disease outbreaks have a way of making pathogen measurement visible. When cases begin appearing across multiple regions, researchers and public health laboratories need to determine what pathogen is present, who has been exposed, how the immune system is responding, and whether patterns are changing over time. These questions depend on different types of assays, each measuring a different part of the biological response.

The ongoing increase in cyclosporiasis cases in the United States offers a timely example. Cyclospora cayetanensis is a foodborne parasite that can cause prolonged gastrointestinal illness. Because infections may be difficult to distinguish from other causes of gastrointestinal disease, laboratory testing and coordinated surveillance are central to identifying cases and investigating potential sources.

The same principle applies well beyond a single outbreak. Whether researchers are studying a parasite, virus, bacterium, or the inflammatory response that follows infection, the quality of the conclusions depends on the quality and appropriateness of the measurement.

Pathogen Detection and Immune-Response Measurement Answer Different Questions

Infectious-disease research commonly involves two related but distinct measurement strategies.

The first is direct pathogen detection. Molecular assays may identify pathogen DNA or RNA, while antigen-based methods detect proteins associated with the organism itself. These approaches can provide evidence that the pathogen is present in the sample.

The second is measurement of the host response. Serological assays detect antibodies generated against pathogen antigens, while cytokine and biomarker assays assess immune activation, inflammation, or tissue injury. These measurements may help researchers investigate exposure, immune status, disease stage, or differences in response between individuals.

No single measurement provides the complete picture. Direct detection, serology, clinical findings, epidemiological information, and immune-response data may each contribute a different layer of evidence.

Measuring Pathogen-Specific Antibodies

Antibody testing is particularly useful when researchers want to examine the immune response to a specific infectious agent.

IgM and IgG measurements can provide different information about the immune response. IgM often appears early following an initial exposure, while IgG may develop later and remain detectable for a longer period. These patterns are not universal, however. Interpretation depends on the pathogen, the timing of sample collection, previous infection or vaccination, assay design, the population being studied, and the potential for cross-reactivity.

For example, CDC guidance for dengue notes that IgG in a single sample is not recommended for diagnosing acute infection, although seroconversion or a substantial rise between paired samples can indicate a recent infection. By contrast, IgM against the hepatitis B core antigen is specifically used as an indicator of recent HBV infection.

Another recently relevant example is of hantavirus. Hantaviruses provide a useful example of why serological assay design requires care. Different hantavirus species and strains circulate in different regions, and human infection can produce severe pulmonary or renal disease. Researchers must consider antigen selection, antibody class, collection timing, geographic context, and the possibility of related viral antibodies contributing to assay signal.

Aviva offers Human Hantavirus IgM and IgG ELISA kits for research involving antibodies against hantavirus in serum or plasma. The IgM assay uses hantavirus antigen-coated wells and an HRP-conjugated detector specific to human IgM, while the IgG kit is designed to detect the corresponding IgG response.

Reagents for Infectious-Disease Assay Development

However, not every research question can be addressed with an existing kit.

Emerging pathogens, uncommon organisms, new variants, and specialized sample types may require researchers to develop or adapt their own assays. In these cases, recombinant pathogen proteins and well-characterized antibodies can serve as starting materials for ELISA, Western blot, lateral-flow, and other immunoassay formats.

Aviva offers infectious-disease research reagents including recombinant dengue virus envelope proteins suitable for ELISA and lateral-flow applications, as well as a Japanese encephalitis virus protein that is immunoreactive with sera from infected individuals and suitable for ELISA and Western blot research.

For targets that are not represented by an existing catalog product, custom recombinant protein production, antibody development, antibody characterization, and ELISA development can provide a path toward a fit-for-purpose assay.

Better Measurement Supports Better Disease Research

Outbreaks such as cyclosporiasis draw attention to the practical importance of laboratory measurement. Researchers need tools that can distinguish one pathogen from another, characterize the antibodies generated after exposure, and examine the broader inflammatory response associated with disease.

Those tools will not always come from a single assay. Pathogen detection, serology, cytokine measurement, and clinical or epidemiological information are most useful when they are treated as complementary sources of evidence.

Aviva Systems Biology supports this work with a broad portfolio of ELISA kits, antibodies, recombinant proteins, and custom assay-development services. From established pathogen-specific assays such as Hantavirus IgG and IgM ELISAs to immunological targets including IFN-γ and TNF-α, our goal is to help researchers select and develop measurements appropriate for the biology they are trying to understand.

Explore Aviva’s infectious-disease and immunology research products, or contact our team to discuss support for a specialized target or assay workflow.

Products discussed are intended for research use. Researchers should review the specifications and intended use of each individual product before incorporating it into a study.